---
title: "LKPC has obtained the drug registration certificate for injectable cefazolin sodium"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244406960.md"
description: "LKPC recently obtained the \"Drug Registration Certificate\" for injectable cefoperazone sodium issued by the National Medical Products Administration. This drug is a third-generation cephalosporin with broad-spectrum antibacterial activity, capable of inhibiting the biosynthesis of bacterial cell walls and stabilizing the broad-spectrum β-lactamases produced by various Gram-positive and Gram-negative bacteria"
datetime: "2025-06-13T09:17:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244406960.md)
  - [en](https://longbridge.com/en/news/244406960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244406960.md)
generator: "portal-rs"
---

# LKPC has obtained the drug registration certificate for injectable cefazolin sodium

According to the Zhitong Finance APP, LKPC (600789.SH) announced that it recently received the "Drug Registration Certificate" (Certificate No.: 2025S01743, 2025S01744) issued by the National Medical Products Administration for injectable cefoperazone sodium, and the drug has been approved for registration.

It is reported that cefoperazone sodium is a third-generation cephalosporin with broad-spectrum antibacterial activity, achieving bactericidal effects by inhibiting the biosynthesis of bacterial cell wall peptidoglycan. It is stable against a variety of broad-spectrum β-lactamases produced by Gram-positive and Gram-negative bacteria (including penicillinase and cephalosporinase)

### Related Stocks

- [600789.CN](https://longbridge.com/en/quote/600789.CN.md)

## Related News & Research

- [Shenzhen Investment Restructures Connected Deals via Property Transfer and Ends Development Pact](https://longbridge.com/en/news/298067700.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**